SciTech Central COVID-19
  • Follow

Accepted Abstracts

How to Control Covid-19 With a Nanobiotherapy?

Gilbert Glady* 
European Bio Immune(G)ene Medecine Association, France

Citation: Glady G (2020) How to Control Covid-19 With a Nanobiotherapy? SciTech Central COVID-19

Received: May 27, 2020         Accepted: May 29, 2020         Published: May 29, 2020


The outbreak of emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) in China has been brought to global attention and declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In a recent study of Nanshan Chen et al., on patients of Wuhan Jinyintan Hospital, Wuhan, China, from the 99 patients with SARSCoV-2 infection, 51% had chronic diseases and they had symptoms of fever (83%), cough (82%) shortness of breath (31%), muscle ache (11%), fatigue (9%), headache (8%), sore throat (5%), rhinorrhoea (4%), chest pain (2%), diarrhoea (2%), and nausea and vomiting (1%). The majority of patients can recover, however, about 25% of patients will progress into severe complications including acute respiratory distress syndrome (ARDS), which may worsen rapidly into respiratory failure, need an intensive care unit (ICU) and even cause multiple organ failure. Depending on the pathophysiological mechanisms supposed to be involved in the development of the various clinical forms of the disease, various types of treatment have been tested with varying degrees of success. We have developed a nanotherapy to block the entry of the virus into the host cell, to reduce its potential for replication and to regulate the immune response against the microbial aggressor.

Key words: COVID-19 inflammatory and infectious mechanisms, Adapted therapies, Nanobiotherapy